MedTrace Logo

Phase I Clinical Trial of CT0181 Cells in the Treatment of Hepatocellular Carcinoma

NCT04973098 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2021-11-04

No results posted yet for this study

Summary

A Phase I Clinical Study of CT0181 cells in Patients with Advanced Hepatocellular Carcinoma

Conditions

Interventions

BIOLOGICAL

CT0181 Cells

5 dose levels each with or without lymphocyte clearance were tentatively determined.

Sponsors & Collaborators

  • CARsgen Therapeutics Co., Ltd.

    collaborator INDUSTRY

  • Peking University

    lead OTHER

Principal Investigators

  • Lin Shen · Peking University Cancer Hospital & Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-05
Primary Completion
2022-08-31
Completion
2023-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04973098 on ClinicalTrials.gov